Ani Pharmaceuticals (ANIP) FCF Margin (2010 - 2026)

Ani Pharmaceuticals has disclosed FCF Margin across 17 years of filings, most recently posting 22.02% for Q1 2026.

• FCF Margin for Q1 2026 came in at 22.02%, up 553.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 20.7% (up 1131.0% YoY), and the FY2025 annual result was 19.4%, up 1162.0% from the prior year.
• FCF Margin came in at 22.02% for Q1 2026 at Ani Pharmaceuticals, up from 11.79% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 36.9% in Q2 2025 to a low of 29.77% in Q1 2022.
• The 5-year median for FCF Margin is 13.94% (2025), against an average of 10.26%.
• Across the five-year window, FCF Margin tumbled 21236 bps in 2022 and soared 4915 bps in 2023, its largest moves.
• Ani Pharmaceuticals' FCF Margin stood at 8.0% in 2022, then soared by 524 bps to 33.92% in 2023, then sank by 100 bps to 0.14% in 2024, then jumped by 8574 bps to 11.79% in 2025, then jumped by 87 bps to 22.02% in 2026.
• The last three FCF Margin figures came in at 22.02% (Q1 2026), 11.79% (Q4 2025), and 13.94% (Q3 2025), per Business Quant data.